Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of bimekizumab for moderate to severe hidradenitis suppurativa
jRCT2041210039Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of bimekizumab in hidradenitis suppurativa (HS), sponsored by UCB. Primary endpoint: Percentage of participants with treatment-emergent adverse events. Started Jul 2021; status: active, not recruiting.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2041210039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210039.